Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 OCF Yield % is 0.55 as of Jul. 22, 2026. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Natera ranks worse than 53.05% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Natera's OCF Yield % or its related term are showing as below:
MEX:NTRA'
s OCF Yield % Range Over the Past 10 Years
Min: -24.92 Med: -3.83 Max: 1.02
Current: 0.55
During the past 13 years, the highest OCF Yield % of Natera was 1.02%. The lowest was -24.92%. And the median was -3.83%.
MEX:NTRA's OCF Yield % is ranked worse than 53.05% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.07
vs MEX:NTRA: 0.55
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Natera OCF Yield % Related Terms
Natera OCF Yield % Historical Data
* Premium members only.
The historical data trend for Natera's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Natera's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (MEX:NTRA) has a OCF Yield % of 0.55 as of Jul. 22, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Natera and its competitors. According to the industry distribution chart, Natera ranks #113 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is Natera's OCF Yield % too high?
Natera's current OCF Yield % is 0.55. The Medical Diagnostics & Research industry median OCF Yield % is 1.07. Natera's value of 0.55 is 48.6% below this industry median. Based on the distribution chart, Natera ranks #113 out of 213 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's OCF Yield % compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #113 out of 213 companies for OCF Yield %. This places Natera in the lower half of its industry. The industry median OCF Yield % is 1.07. Natera's value of 0.55 is 48.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.07, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natera's current OCF Yield % of 0.55 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current OCF Yield % is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current OCF Yield % is 0.55 and 48.6% below the Medical Diagnostics & Research industry median of 1.07. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Natera (MEX:NTRA), the current OCF Yield % is 0.55 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
OCF Yield %: 0.55
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
Industry Position: 48.6% below the Medical Diagnostics & Research median (#113 of 213)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
